These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 9593762

  • 1. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria.
    Lamping N, Dettmer R, Schröder NW, Pfeil D, Hallatschek W, Burger R, Schumann RR.
    J Clin Invest; 1998 May 15; 101(10):2065-71. PubMed ID: 9593762
    [Abstract] [Full Text] [Related]

  • 2. Monoclonal antibodies to murine lipopolysaccharide (LPS)-binding protein (LBP) protect mice from lethal endotoxemia by blocking either the binding of LPS to LBP or the presentation of LPS/LBP complexes to CD14.
    Le Roy D, Di Padova F, Tees R, Lengacher S, Landmann R, Glauser MP, Calandra T, Heumann D.
    J Immunol; 1999 Jun 15; 162(12):7454-60. PubMed ID: 10358200
    [Abstract] [Full Text] [Related]

  • 3. Reactivity of murine and human recombinant LPS-binding protein (LBP) within LPS and gram negative bacteria.
    Lengacher S, Jongeneel CV, Le Roy D, Lee JD, Kravchenko V, Ulevitch RJ, Glauser MP, Heumann D.
    J Inflamm; 1999 Jun 15; 47(4):165-72. PubMed ID: 9144073
    [Abstract] [Full Text] [Related]

  • 4. Antagonistic effects of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein on lipopolysaccharide-induced cytokine release by mononuclear phagocytes. Competition for binding to lipopolysaccharide.
    Dentener MA, Von Asmuth EJ, Francot GJ, Marra MN, Buurman WA.
    J Immunol; 1993 Oct 15; 151(8):4258-65. PubMed ID: 8409400
    [Abstract] [Full Text] [Related]

  • 5. Lipopolysaccharide-binding protein is required to combat a murine gram-negative bacterial infection.
    Jack RS, Fan X, Bernheiden M, Rune G, Ehlers M, Weber A, Kirsch G, Mentel R, Fürll B, Freudenberg M, Schmitz G, Stelter F, Schütt C.
    Nature; 1997 Oct 16; 389(6652):742-5. PubMed ID: 9338787
    [Abstract] [Full Text] [Related]

  • 6. Differential regulation of lipopolysaccharide (LPS) activation pathways in mouse macrophages by LPS-binding proteins.
    Amura CR, Kamei T, Ito N, Soares MJ, Morrison DC.
    J Immunol; 1998 Sep 01; 161(5):2552-60. PubMed ID: 9725255
    [Abstract] [Full Text] [Related]

  • 7. Modulatory effects of sCD14 and LBP on LPS-host cell interactions.
    Kitchens RL, Thompson PA.
    J Endotoxin Res; 2005 Sep 01; 11(4):225-9. PubMed ID: 16176659
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.
    Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, Przetak M, Chow J, Gusovsky F, Christ WJ, Rossignol DP.
    J Pharmacol Exp Ther; 2003 Mar 01; 304(3):1093-102. PubMed ID: 12604686
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of LPS-responses by synthetic peptides derived from LBP associates with the ability of the peptides to block LBP-LPS interaction.
    Araña Mde J, Vallespi MG, Chinea G, Vallespi GV, Rodriguez-Alonso I, Garay HE, Buurman WA, Reyes O.
    J Endotoxin Res; 2003 Mar 01; 9(5):281-91. PubMed ID: 14577844
    [Abstract] [Full Text] [Related]

  • 10. Lipopolysaccharide (LPS) binding protein catalyzes binding of LPS to lipoproteins.
    Wurfel MM, Wright SD.
    Prog Clin Biol Res; 1995 Mar 01; 392():287-95. PubMed ID: 8524933
    [Abstract] [Full Text] [Related]

  • 11. Effects of site-directed mutagenesis of basic residues (Arg 94, Lys 95, Lys 99) of lipopolysaccharide (LPS)-binding protein on binding and transfer of LPS and subsequent immune cell activation.
    Lamping N, Hoess A, Yu B, Park TC, Kirschning CJ, Pfeil D, Reuter D, Wright SD, Herrmann F, Schumann RR.
    J Immunol; 1996 Nov 15; 157(10):4648-56. PubMed ID: 8906845
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. LPS-binding protein-deficient mice have an impaired defense against Gram-negative but not Gram-positive pneumonia.
    Branger J, Florquin S, Knapp S, Leemans JC, Pater JM, Speelman P, Golenbock DT, van der Poll T.
    Int Immunol; 2004 Nov 15; 16(11):1605-11. PubMed ID: 15452020
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Recombinant bovine soluble CD14 reduces severity of experimental Escherichia coli mastitis in mice.
    Lee JW, Paape MJ, Zhao X.
    Vet Res; 2003 Nov 15; 34(3):307-16. PubMed ID: 12791240
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.